The study of CML showed that CML patients often had lower serum BATF2 mRNA expression levels than healthy individuals; the down-regulation of BATF2 gene expression is related to BCR-ABL inhibition and participates in the occurrence and development of CML [8]. This evidence concerns the gene BATF2 and chronic myelogenous leukemia, BCR-ABL1 positive.